Lilly's Foundayo Cuts Diabetes Risk 57%, Cardiovascular Risk 18% in New Data
LLY sits 60% above its 52-week low of $725.31.
Summary
New data show Foundayo 17.2 mg reduced predicted long-term risk of type 2 diabetes by 57% and cardiovascular disease by 18% versus placebo. This is the first disclosure of specific risk-reduction percentages for the oral obesity drug, which was approved by the FDA in August. The data strengthen the case for Foundayo as a differentiated option in Lilly's obesity portfolio, alongside Mounjaro and Zepbound. The company is already preparing global regulatory submissions for retatrutide, its next-generation obesity drug, and this new evidence could support broader label claims for Foundayo. Investors will watch for further analyses and potential inclusion in treatment guidelines.
At the time of this announcement, LLY was trading at $1,158.84 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $725.31 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.